Search Results - "Gerardelli, Laura"

In vivo vulnerabilities to GPX4 and HDAC inhibitors in drug-persistent versus drug-resistant BRAFV600E lung adenocarcinoma by Nokin, Marie-Julie, Darbo, Elodie, Richard, Elodie, San José, Sonia, de Hita, Sergio, Prouzet-Mauleon, Valérie, Turcq, Béatrice, Gerardelli, Laura, Crake, Rebekah, Velasco, Valérie, Koopmansch, Benjamin, Lambert, Frederic, Xue, Jenny Y, Sang, Ben, Horne, Julie, Ziemons, Eric, Villanueva, Alberto, Blomme, Arnaud, Herfs, Michael, Cataldo, Didier, Calvayrac, Olivier, Porporato, Paolo, Nadal, Ernest, Lito, Piro, Jänne, Pasi A, Ricciuti, Biagio, Awad, Mark M, Ambrogio, Chiara, Santamaría, David

“…The current targeted therapy for BRAFV600E-mutant lung cancer consists of a dual blockade of RAF/MEK kinases often combining dabrafenib/trametinib (D/T). This…”
Get full text

In vivo vulnerabilities to GPX4 and HDAC inhibitors in drug-persistent versus drug-resistant BRAF V600E lung adenocarcinoma by Nokin, Marie-Julie, Darbo, Elodie, Richard, Elodie, San José, Sonia, de Hita, Sergio, Prouzet-Mauleon, Valérie, Turcq, Béatrice, Gerardelli, Laura, Crake, Rebekah, Velasco, Valérie, Koopmansch, Benjamin, Lambert, Frederic, Xue, Jenny Y, Sang, Ben, Horne, Julie, Ziemons, Eric, Villanueva, Alberto, Blomme, Arnaud, Herfs, Michael, Cataldo, Didier, Calvayrac, Olivier, Porporato, Paolo, Nadal, Ernest, Lito, Piro, Jänne, Pasi A, Ricciuti, Biagio, Awad, Mark M, Ambrogio, Chiara, Santamaría, David

“…The current targeted therapy for BRAF -mutant lung cancer consists of a dual blockade of RAF/MEK kinases often combining dabrafenib/trametinib (D/T). This…”
Get full text

In vivo vulnerabilities to GPX4 and HDAC inhibitors in drug-persistent versus drug-resistant BRAFV600E lung adenocarcinoma by Nokin, Marie-Julie, Darbo, Elodie, Richard, Elodie, San José, Sonia, de Hita, Sergio, Prouzet-Mauleon, Valérie, Turcq, Béatrice, Gerardelli, Laura, Crake, Rebekah, Velasco, Valérie, Koopmansch, Benjamin, Lambert, Frederic, Xue, Jenny Y., Sang, Ben, Horne, Julie, Ziemons, Eric, Villanueva, Alberto, Blomme, Arnaud, Herfs, Michael, Cataldo, Didier, Calvayrac, Olivier, Porporato, Paolo, Nadal, Ernest, Lito, Piro, Jänne, Pasi A., Ricciuti, Biagio, Awad, Mark M., Ambrogio, Chiara, Santamaría, David

“…The current targeted therapy for BRAFV600E-mutant lung cancer consists of a dual blockade of RAF/MEK kinases often combining dabrafenib/trametinib (D/T). This…”
Get full text